Retrospective analysis shows improved olfactory function and reduced inflammatory factors in AECRS patients, indicating effective treatment.
This study is intended to expound the effect of clarithromycin combined with oxymetazoline hydrochloride ( OZH ) spray in acute exacerbations of chronic rhinosinusitis ( AECRS ). Patients with AECRS were retrospectively collected and divided into a control group and an observation group. The control group received clarithromycin, and the observation group received OZH spray in addition to clarithromycin. Symptom resolution time, nasal mucociliary transmission velocity, nasal endoscopy score, olfactory function, serum inflammatory factor levels, incidence of adverse reactions, and 6‐month recurrence were recorded. After treatment, the observation group showed shorter resolution times for headache, runny nose, nasal congestion, and nasal mucosal edema; higher nasal mucociliary transport rate ( MTR ) and clearance ( MCC ); lower Lund‐Kennedy score; more Grades I cases; fewer Grades III cases; lower levels of serum IL ‐6, TNF ‐α, hs‐ CRP , IL ‐8, and IL ‐1β; and lower recurrence rate than the control group ( p < 0.05). The incidence of adverse reactions in the two groups was not statistically significant ( p > 0.05). Clarithromycin combined with OZH spray is more effective in patients with AECRS , which can shorten symptom resolution time, increase nasal MTR , improve olfactory function, reduce inflammation and recurrence rates, and have a high degree of safety.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: